SOURCE: Rosetta Genomics, Ltd.

October 16, 2013 08:30 ET

Rosetta Genomics' Cancer Origin Test Incorporated Into Altos Solutions' OncoEMR® Software Electronic Medical Record

Automated Oncology EMR Allows Oncologists to Identify Appropriate Cancer of Unknown Primary Patients and to Order the Cancer Origin Test Through Rosetta's Web Portal

PRINCETON, NJ and REHOVOT, ISRAEL--(Marketwired - Oct 16, 2013) - Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that the Rosetta Cancer Origin Test™ will be incorporated into Altos Solutions, Inc.'s (Altos) Electronic Medical Records (EMR) system, OncoEMR®.

Beginning November 1, 2013, Rosetta's Cancer Origin Test will be available through the Altos OncoEMR system as part of a three-faceted program to help oncologists determine the tumor origin in patients with Cancer of Unknown or Uncertain Primary (CUP). The first step in providing clinical decision support is OncoEMR's proprietary identification logic to determine eligible CUP patients. Next, OncoEMR automates test ordering by incorporating the ordering process directly into the practices' workflow. Ultimately, the system will provide oncologists with an automated result-reporting feature that will be incorporated into the oncologists' workflow via the Rosetta physicians' web portal, which is both HIPAA and HL7 compliant.

"We are very excited to have our Cancer Origin Test incorporated into OncoEMR as it will enhance and automate the physician's ability to identify, diagnose and determine optimal treatment plans for patients who present with CUP," stated Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics. "Developments in targeted cancer therapies are driving the need for more accurate classification of tumor types, which help to guide treatment decisions. Our Cancer Origin Test accurately identifies the primary tumor type in primary and metastatic cancer including CUP, which could benefit the estimated 200,000 patients per year in the U.S. who present with this unclear diagnosis."

"The Altos partnership with Rosetta Genomics demonstrates the dedication that we have to practices and patients within the Altos network and the commitment we have to enhancing cancer care with technology," stated Brad Frazier, Vice President of Business Development with Altos Solutions, Inc. "Through our Clinical Decision Gateways™ group, we are continuously assessing opportunities to help improve the clinical workflow of our clients and to integrate emerging oncology diagnostics into our technology platforms."

"Clearly, this is an exciting opportunity for Rosetta. Altos Solutions is the first U.S. company to offer oncology practices a platform of integrated, knowledge-based products and services to collect, benchmark and analyze data. We look forward to the initial rollout of this integration, starting this month, to the entire network of oncology physicians who utilize OncoEMR, and completion of the integration by the end of November. We expect these solutions to further enhance the awareness and utilization of our Cancer Origin Test as we continue to focus on driving demand for testing services," concluded Mr. Berlin.

About Altos Solutions, Inc.
Altos Solutions, Inc. is the pioneer in secure web-based oncology-specific software applications, focusing on intuitive electronic medical records, practice management with integrated medical billing, real-time comparative analytics, and patient and provider portals. Oncology Metrics, a division of Altos Solutions, Inc., fosters a network of independent community-based oncology practices to provide a platform of knowledge-based products and services. Altos Solutions is the first company in the U.S. to offer oncology practices an oncology-specific EMR application combined with services to collect, benchmark and analyze the data contained in these records. Oncology practices maintain sole control and ownership of their proprietary information entered or converted into OncoEMR. With an installed base of over 1,200 oncology clinicians and thousands of daily users, OncoEMR is the answer for all oncology practices from the solo practitioner oncologist, multi-location cancer centers and hospital-based ambulatory cancer centers. Altos Solutions is headquartered in Pleasanton, California. To learn more about Altos Solutions, call (888) 662-6367 or 888-OncoEMR, internationally call +1 (925) 425-0093 or visit

About Rosetta Cancer Testing Services
Rosetta Cancer Tests are a series of microRNA-based diagnostic testing services offered by Rosetta Genomics. The Rosetta Cancer Origin Test™ can accurately identify the primary tumor type in primary and metastatic cancer including cancer of unknown or uncertain primary (CUP). The Rosetta Mesothelioma Test™ diagnoses mesothelioma, a cancer connected to asbestos exposure. The Rosetta Lung Cancer Test™ accurately identifies the four main subtypes of lung cancer using small amounts of tumor cells. The Rosetta Kidney Cancer Test™ accurately classifies the four most common kidney tumors: clear cell renal cell carcinoma (RCC), papillary RCC, chromophobe RCC and the benign oncocytoma. Rosetta's assays are designed to provide objective diagnostic data; it is the treating physician's responsibility to diagnose and administer the appropriate treatment. In the U.S. alone, Rosetta Genomics estimates that 200,000 patients a year may benefit from the Cancer Origin Test, 60,000 from the Mesothelioma Test, 65,000 from the Kidney Cancer Test and 226,000 patients from the Lung Cancer Test. The Company's assays are offered directly by Rosetta Genomics in the U.S., and through distributors around the world. For more information, please visit Parties interested in ordering the test can contact Rosetta Genomics at (215) 382-9000 ext. 309.

About Rosetta Genomics
Rosetta develops and commercializes a full range of microRNA-based molecular diagnostics. Founded in 2000, Rosetta's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools. Rosetta's cancer testing services are commercially available through its Philadelphia-based CAP-accredited, CLIA-certified lab. Frost & Sullivan recognized Rosetta Genomics with the 2012 North American Next Generation Diagnostics Entrepreneurial Company of the Year Award.

Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, Rosetta's Cancer of Origin Test, the Cancer Origin Test improving the ability of physicians to accurately diagnose CUP, the Cancer Origin Test's ability to help physicians to optimize treatment, Rosetta's development or commercialization of molecular diagnostics, the market acceptance of Rosetta's cancer testing services, particularly the Cancer Origin Test, Rosetta's expectation that the integration of the Cancer Origin Test into Altos Solutions' OncoEMR will enhance the awareness and utilization of the Cancer Origin Test, as well as the expected timeline for the roll-out of this integration, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2012 as filed with the SEC. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

Contact Information